- Home
- ZNTL vs RMM Comparison
ZNTL vs RMM Comparison
Compare ZNTL & RMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZNTL | RMM |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 285.6M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | RMM |
|---|---|---|
| Price | $2.55 | $13.55 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.60 | N/A |
| AVG Volume (30 Days) | ★ 597.1K | 41.5K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.87 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,425,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $12.55 |
| 52 Week High | $3.95 | $14.88 |
Technical Indicators
Market Signals| Indicator | ZNTL | RMM |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 31.15 |
| Support Level | $1.29 | N/A |
| Resistance Level | $2.69 | $13.99 |
| Average True Range (ATR) | 0.21 | 0.26 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 37.92 | 4.90 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.